Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73635449" target="_blank" >RIV/61989592:15110/25:73635449 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1558767325000825?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1558767325000825?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clgc.2025.102382" target="_blank" >10.1016/j.clgc.2025.102382</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project

Popis výsledku v původním jazyce

Introduction: The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically in the last few years, with different options being available, and with no data comparing these new systemic therapies. Therefore, the value of real-world outcomes (RWO) becomes of great interest to understand the effectiveness of these treatments. Here we analyze the outcome of metastatic RCC patients treated with first-line cabozantinib in a retrospective cohort from the Czech Republic and Poland Methods: Patients with metastatic RCC treated with first-line cabozantinib in the Czech Republic and Poland were included in a retrospective fashion. Data were collected regarding progression-free survival (PFS), overall survival (OS), response rate and toxicity, with a focus in several subgroups of interest. Results: We identified 146 patients, the majority of them (80.8%) with clear cell RCC (ccRCC). The median OS was 14.7 months, and the median PFS 8.2 months, with a response rate of 30.3%. CTCAE v3.0 grade 3+4 toxicity was presented in 34.2% of patients. The efficacy of Cabozantinib was maintained regardless of histologic subtype and the presence of sarcomatoid component, although PFS and OS data were numerically better for nonclear cell RCC. Bone and liver metastases were confirmed as independent factor for poor survival in the multivariate analysis. Conclusions: In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data can be considered comparable with what has been seen in randomised clinical trials, considering the inherent bias present in RWO studies.

Název v anglickém jazyce

Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project

Popis výsledku anglicky

Introduction: The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically in the last few years, with different options being available, and with no data comparing these new systemic therapies. Therefore, the value of real-world outcomes (RWO) becomes of great interest to understand the effectiveness of these treatments. Here we analyze the outcome of metastatic RCC patients treated with first-line cabozantinib in a retrospective cohort from the Czech Republic and Poland Methods: Patients with metastatic RCC treated with first-line cabozantinib in the Czech Republic and Poland were included in a retrospective fashion. Data were collected regarding progression-free survival (PFS), overall survival (OS), response rate and toxicity, with a focus in several subgroups of interest. Results: We identified 146 patients, the majority of them (80.8%) with clear cell RCC (ccRCC). The median OS was 14.7 months, and the median PFS 8.2 months, with a response rate of 30.3%. CTCAE v3.0 grade 3+4 toxicity was presented in 34.2% of patients. The efficacy of Cabozantinib was maintained regardless of histologic subtype and the presence of sarcomatoid component, although PFS and OS data were numerically better for nonclear cell RCC. Bone and liver metastases were confirmed as independent factor for poor survival in the multivariate analysis. Conclusions: In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data can be considered comparable with what has been seen in randomised clinical trials, considering the inherent bias present in RWO studies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Genitourinary Cancer

ISSN

—

e-ISSN

1938-0682

Svazek periodika

23

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

102382

Kód UT WoS článku

001527301300001

EID výsledku v databázi Scopus

2-s2.0-105008985985